Physician profile
Philip Oro
NPI 1073993549
$1,431.61
in general payments reported to CMS, 2019-2025
22 companies · $596 in 2025
The $596 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $237 · 2024: $599 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $247.73 | 2024-2025 | |
| Glaxosmithkline, LLC. | $216.33 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $194.29 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $146.26 | 2023-2025 | Descovy |
| Novo Nordisk INC | $70.00 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Seqirus USA INC | $58.86 | 2025 | Flucelvax |
| Amgen INC. | $57.90 | 2023-2024 | Repatha, Otezla |
| Pfizer INC. | $55.85 | 2023-2025 | |
| Exact Sciences Corporation | $43.22 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $43.05 | 2024-2025 | Spravato |
| Merck Sharp & Dohme LLC | $34.91 | 2023-2025 | Capvaxive, Pneumovax 23, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $32.58 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.34 | 2024 | Trulance, Xifaxan |
| Astrazeneca Pharmaceuticals LP | $30.72 | 2025 | Breztri |
| Insmed, INC. | $30.04 | 2025 | Brinsupri, Arikayce |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $27.46 | 2024 | |
| Abbott Laboratories | $24.05 | 2024 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $20.77 | 2025 | Gemtesa |
| Corium, LLC | $18.61 | 2024 | Azstarys |
| Cleerly, INC. | $16.63 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Aimmune Therapeutics, INC. | $15.93 | 2024 | |
| Viiv Healthcare Company | $15.08 | 2024 | Apretude |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Oro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.